Medicare AdvantageDocumentationMedium impact
MA08.073q, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated medical necessity criteria for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors. The changes affect ophthalmology billing and will require updated documentation to meet new medical necessity requirements.
Action Required
By January 1, 2025: Ophthalmology providers and billing team must review and implement updated medical necessity criteria for intravitreal VEGF injections. Update EMR templates and encounter forms to ensure documentation meets new Medicare Advantage requirements. Review current pending claims to ensure compliance with new criteria.